SANA vs. RARE

Last updated Apr 1, 2026

Compare and contrast key facts about Sana Biotechnology, Inc. (SANA) and Ultragenyx Pharmaceutical Inc. (RARE).

Performance

SANA vs. RARE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sana Biotechnology, Inc. (SANA) and Ultragenyx Pharmaceutical Inc. (RARE). The values are adjusted to include any dividend payments, if applicable.

SANA vs. RARE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
SANA Sana Biotechnology, Inc.	-29.24%	149.69%	-60.05%	3.29%	-74.48%	-55.90%
RARE Ultragenyx Pharmaceutical Inc.	-8.91%	-45.33%	-12.02%	3.22%	-44.90%	-45.75%

Fundamentals

Market Cap SANA : $729.31M RARE : $2.09B
EPS SANA : -$0.97 RARE : -$5.79
PB Ratio SANA : 4.53 RARE : 129.52
Total Revenue (TTM) SANA : $0.00 RARE : $672.72M
Gross Profit (TTM) SANA : $0.00 RARE : $564.07M
EBITDA (TTM) SANA : -$250.32M RARE : -$488.57M

Returns By Period

In the year-to-date period, SANA achieves a -29.24% return, which is significantly lower than RARE's -8.91% return.

SANA

• 1D: 7.46%
• 1M: -31.59%
• YTD: -29.24%
• 6M: -18.87%
• 1Y: 71.43%
• 3Y*: -4.14%
• 5Y*: -38.22%
• 10Y*: —

RARE

• 1D: 8.55%
• 1M: -10.43%
• YTD: -8.91%
• 6M: -30.35%
• 1Y: -42.14%
• 3Y*: -19.46%
• 5Y*: -28.64%
• 10Y*: -10.90%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SANA vs. RARE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SANA

SANA Risk / Return Rank: 68
SANA Sharpe Ratio Rank: 66
SANA Sortino Ratio Rank: 72
SANA Omega Ratio Rank: 68
SANA Calmar Ratio Rank: 68
SANA Martin Ratio Rank: 65

RARE

RARE Risk / Return Rank: 15
RARE Sharpe Ratio Rank: 16
RARE Sortino Ratio Rank: 21
RARE Omega Ratio Rank: 19
RARE Calmar Ratio Rank: 12
RARE Martin Ratio Rank: 9

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SANA vs. RARE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sana Biotechnology, Inc. (SANA) and Ultragenyx Pharmaceutical Inc. (RARE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SANA	RARE	Difference
Sharpe ratio Return per unit of total volatility	0.68	-0.59	+1.26
Sortino ratio Return per unit of downside risk	1.69	-0.42	+2.11
Omega ratio Gain probability vs. loss probability	1.20	0.93	+0.28
Calmar ratio Return relative to maximum drawdown	1.25	-0.81	+2.06
Martin ratio Return relative to average drawdown	2.59	-1.53	+4.12
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SANA vs. RARE - Sharpe Ratio Comparison

The current SANA Sharpe Ratio is 0.68, which is higher than the RARE Sharpe Ratio of -0.59. The chart below compares the historical Sharpe Ratios of SANA and RARE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	SANA	RARE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.68	-0.59	+1.26
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.32	-0.53	+0.21
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.20	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.32	-0.10	-0.23

Correlation

The correlation between SANA and RARE is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

SANA vs. RARE - Dividend Comparison

Neither SANA nor RARE has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

SANA vs. RARE - Drawdown Comparison

The maximum SANA drawdown since its inception was -96.92%, which is greater than RARE's maximum drawdown of -89.57%. Use the drawdown chart below to compare losses from any high point for SANA and RARE.

Drawdown Indicators

	SANA	RARE	Difference
Max Drawdown Largest peak-to-trough decline	-96.92%	-89.57%	-7.35%
Max Drawdown (1Y) Largest decline over 1 year	-54.73%	-55.36%	+0.63%
Max Drawdown (5Y) Largest decline over 5 years	-95.83%	-84.01%	-11.82%
Max Drawdown (10Y) Largest decline over 10 years	—	-89.57%	—
Current Drawdown Current decline from peak	-93.38%	-88.19%	-5.19%
Average Drawdown Average peak-to-trough decline	-81.09%	-54.28%	-26.81%
Ulcer Index Depth and duration of drawdowns from previous peaks	26.43%	29.21%	-2.78%

Volatility

SANA vs. RARE - Volatility Comparison

Sana Biotechnology, Inc. (SANA) has a higher volatility of 23.86% compared to Ultragenyx Pharmaceutical Inc. (RARE) at 18.67%. This indicates that SANA's price experiences larger fluctuations and is considered to be riskier than RARE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SANA	RARE	Difference
Volatility (1M) Calculated over the trailing 1-month period	23.86%	18.67%	+5.19%
Volatility (6M) Calculated over the trailing 6-month period	67.34%	67.87%	-0.53%
Volatility (1Y) Calculated over the trailing 1-year period	106.35%	71.96%	+34.39%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	118.84%	54.11%	+64.73%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	118.80%	55.61%	+63.19%

Financials